Asset Details
Do you wish to reserve the book?
Prevention of host-to-host transmission by SARS-CoV-2 vaccines
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prevention of host-to-host transmission by SARS-CoV-2 vaccines
Do you wish to request the book?
Prevention of host-to-host transmission by SARS-CoV-2 vaccines
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Prevention of host-to-host transmission by SARS-CoV-2 vaccines
2022
Overview
As the number of individuals vaccinated against SARS-CoV-2 rises worldwide, population-level data regarding the vaccines' ability to reduce infection are being generated. Randomised trials have shown that these vaccines dramatically reduce symptomatic COVID-19; however, less is known about their effects on transmission between individuals. The natural course of infection with SARS-CoV-2 involves infection of the respiratory epithelia and replication within the mucosa to sufficient viral titres for transmission via aerosol particles and droplets. Here we discuss the available data on the existing, approved SARS-CoV-2 vaccines' capacity to reduce transmissibility by reducing primary infection, viral replication, capacity for transmission, and symptomaticity. The potential for mucosal-targeted SARS-CoV-2 vaccine strategies to more effectively limit transmission than intramuscular vaccines is considered with regard to known immunological mechanisms. Finally, we enumerate the population-level effects of approved vaccines on transmission through observational studies following clinical trials and vaccine distribution in real-world settings.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Antibodies, Viral - biosynthesis
/ Antibodies, Viral - immunology
/ Antigens
/ COVID-19
/ COVID-19 - prevention & control
/ COVID-19 Vaccines - adverse effects
/ COVID-19 Vaccines - immunology
/ Humans
/ Immunoglobulin A - biosynthesis
/ Immunoglobulin A - immunology
/ Immunoglobulin G - biosynthesis
/ Immunoglobulin G - immunology
/ Mucosa
/ Proteins
/ Severe acute respiratory syndrome coronavirus 2
/ Vaccines
